Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease
Read or download our press releases for all latest news about our company, research & development activities and updates for investors. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with Oxurion associates. Be sure to check in regularly for the latest Oxurion press releases or just subscribe to our mailing list to receive regular updates.
Oxurion is committed and engaged to communicate openly with all relevant stakeholders. Regarding any press enquiries, comments or questions about Oxurion, please contact our Corporate Communications department:
Wouter Piepers Global Head of Corporate Communications and Investor Relations
The materials (such as images, photographs, illustrations, icons, texts, video clips, written and other proprietary information) contained in this Media Center (the “Materials”) are the valuable property of ThromboGenics NV and/or its licensors. ThromboGenics and/or its licensors, as appropriate, reserve all patent, copyright and other proprietary rights to the Materials, including all design, manufacturing, reproduction, use, and sales rights thereto. You may download, print and use the Materials solely for the permitted purpose as specified in the respective “Asset Details” or – if ThromboGenics provides you with a download link – for any purpose, provided you do not delete or change any copyright or trademark, or distort, mutilate or otherwise modify the proprietary information in a manner that may be prejudicial to ThromboGenics or its licensors. To allow for design, content and specification improvements, the Materials in this Media Center are subject to change at any time, without notice. Reproduction of this Media Center or portions thereof without prior written approval of ThromboGenics is prohibited.